TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12870063
Drug: Intravenous penicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous penicillin, 6 million units per day (one million unit every four hours) for seven days
Study: 10571602
Drug: Simethicone (84
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone (84 mg t.d.s.)
Study: 1905214
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition and sucralfate (1 g by nasogastric tube every 4 hrs)
Study: 1905214
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition and ranitidine (50 mg iv every 6 hrs)
Study: 1905214
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition and sucralfate
Study: 1905214
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition and ranitidine
Study: 26505163
Drug: Δ9‐THC (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ9‐THC (8 mg)
Study: 26505163
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (5 mg/10 mg diazepam)
Study: 25194996
Drug: Primary closure
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary closure of buccal mucosal graft harvest site
Study: 25194996
Drug: Nonclosure of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonclosure of buccal mucosal graft harvest site
Study: 17663046
Drug: Millimeter-range electromagnetic
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Millimeter-range electromagnetic radiation therapy
Study: 9177976
Drug: Oxandrolone (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (0.05 mg/kg/day)
Study: 9177976
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low dose oxandrolone and oestrogen
Study: 1609044
Drug: Bovine cortex
Normalized name: adrenal cortex extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine cortex phosphatidylserine (BC‐PS; 100 mg t.i.d.)
Study: 3907394
Drug: Sustained-release terbutaline
Normalized name: terbutaline Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release terbutaline sulphate 5 mg twice a day
Study: 3907394
Drug: Ordinary tablets
Normalized name: phenazopyridine Oral Tablet [Azo Urinary Pain Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary tablets 2.5 mg three times a day
Study: 27015546
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone (5 mg)
Study: 27015546
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (5 mg)
Study: 24693959
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus interlaminar epidural steroid injection
Study: 24693959
Drug: Interlaminar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interlaminar epidural steroid injection
Study: 22861076
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine patches (700 mg)
Study: 16005120
Drug: Virosomal influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosomal influenza vaccine
Study: 16104444
Drug: Conventional subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional subunit vaccine
Study: 12426518
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa administered once weekly (n = 17)
Study: 12426518
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa administered 3 times weekly (n = 15)
Study: 12426518
Drug: Epoetin administered
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin administered 3 times weekly (n = 15)
Study: 12426518
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (once and three times weekly) and Epoetin (three times weekly)
Study: 10233652
Drug: Chart as
Normalized name: Stachybotrys chartarum
DrugBank: Stachybotrys chartarum (DB10847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chart as an aide memoire for topical medications
Study: 7805919
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) injection (1 mg/kg)
Study: 1655177
Drug: Piroxicam 5
Normalized name: piroxicam 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 5 mg daily
Study: 6336951
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 1.5 g three times daily for 5 days starting on the first day of menstruation
Study: 6336951
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (DS) 50 mg three times on the first day followed by 25 mg three times daily for 4 days
Study: 29539585
Drug: Exposure-based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based Cognitive Behavioral Therapy (eb-CBT)
Study: 27283792
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg subcutaneous (s.c.) relamorelin
Study: 22262484
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion during high sodium intake (HS; 300 mmol sodium/day)
Study: 22262484
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline infusion during low sodium intake (LS; 30 mmol sodium/day)
Study: 19075273
Drug: Chemotherapy (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (first cycle)
Study: 19075273
Drug: Chemotherapy (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (second cycle)
Study: 18080339
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg daily
Study: 7666089
Drug: PVI 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVI 5‐FU 300 mg/m2/d plus IFN 5 MU subcutaneously three times weekly
Study: 2759973
Drug: Ephedrine-caffeine mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine-caffeine mixture (1 mg/kg ephedrine, 2.5 mg/kg caffeine)
Study: 25757446
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rectal diclofenac
Study: 31612188
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral diclofenac
Study: 31612188
Drug: 75 mg/3
Normalized name: cran/vitC/mannose/FOS/bromeln 3,875 mg/30 mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/3 ml intramuscular diclofenac sodium
Study: 31612188
Drug: 75 mg/3
Normalized name: cran/vitC/mannose/FOS/bromeln 3,875 mg/30 mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/3 ml intravenous diclofenac
Study: 28558714
Drug: ProF-Cog intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ProF-Cog intervention including falls risk assessment, tailored intervention (dementia care mapping, comprehensive geriatric assessment, occupational therapy, twice-weekly exercise for 6 months)
Study: 25895497
Drug: Desmopressin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.3 μg/kg
Study: 19436663
Drug: Rosuvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (5 mg) once daily
Study: 10328277
Drug: Rectal diazepam
Normalized name: diazepam Rectal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diazepam (DZP) gel
Study: 7001487
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg protacine 3-times daily for 21 days
Study: 7001487
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oxyphenbutazone 3-times daily for 21 days
Study: 7001487
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg protacine
Study: 7001487
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oxyphenbutazone
Study: 31809955
Drug: Torsemide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torsemide (0.1 mg/kg PO q 12 h)
Study: 31809955
Drug: Furosemide (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (2.0 mg/kg PO q 12 h)
Study: 31809955
Drug: Diuretic groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic groups (Torsemide and Furosemide)
Study: 26783233
Drug: Systematic clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic clinical testing including exercise testing, drug provocation, advanced cardiac imaging, and genetic testing.
Study: 26783233
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator therapy.
Study: 22622147
Drug: XELOX plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX plus bevacizumab using a dose-dense biweekly cycle (Q2W)
Study: 11932561
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (GH) treatment, 0.11-0.14 IU.kg-1, daily, s.c.
Study: 11932561
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (standard therapy)
Study: 7632064
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg/d)
Study: 7632064
Drug: Griseofulvin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin (1000 mg/d)
Study: 2695448
Drug: 1-week interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week interval schedule of endoscopic injection sclerotherapy
Study: 2695448
Drug: 2-week interval
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week interval schedule of endoscopic injection sclerotherapy
Study: 19444731
Drug: Individual outpatient
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual outpatient alcoholism treatment
Study: 19444731
Drug: Couples outpatient
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couples outpatient alcoholism treatment
Study: 12364460
Drug: GH 1
Normalized name: Cough 100mg/5ml Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 1 micro g/kg
Study: 12364460
Drug: GH 3
Normalized name: Zicam Cough 3.3 MG/ACTUAT Oral Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 3 micro g/kg
Study: 12364460
Drug: GH 6
Normalized name: Zicam Cough 6 MG/ACTUAT Oral Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 6 micro g/kg
Study: 8021626
Drug: Bright colors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright colors (e.g., pink, blue, red)
Study: 8021626
Drug: Dark colors
Normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark colors (e.g., brown, black, gray)
Study: 2688780
Drug: Prescriptive treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptive treatment
Study: 2688780
Drug: Exploratory treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exploratory treatment
Study: 26518352
Drug: Electric fan
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electric fan therapy
Study: 23941470
Drug: Exercise-based programme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise-based programme (ARNI), 24 hours of one-to-one training by an Exercise Professional, plus at least 2 hours weekly unsupervised exercise, over 12-14 weeks
Study: 21675444
Drug: Silver sulfadiazine
Normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver sulfadiazine cream, changed twice a day
Study: 18608103
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (5 g/d)
Study: 12401636
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of neostigmine plus 3 mg/kg of prilocaine diluted with saline to a total dose of 40 mL
Study: 12401636
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of saline plus 3 mg/kg of prilocaine diluted with saline to a total dose of 40 mL
Study: 7778354
Drug: physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: physical therapy (cold foot-baths)
Study: 647213
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin infusion (2.6 U/h)
Study: 647213
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin infusion (10.6 U/h)
Study: 647213
Drug: Both insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both insulin infusions (low and high dose)
Study: 29462095
Drug: Topical testosterone
Normalized name: testosterone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical testosterone applied 3 times a week for 12 weeks
Study: 29462095
Drug: Topical estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estrogen applied 3 times a week for 12 weeks
Study: 11007214
Drug: PDT (Photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT (Photodynamic Therapy)
Study: 27516420
Drug: PDL-PDT (Pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDL-PDT (Pulsed Dye Laser-mediated Photodynamic Therapy)
Study: 24738516
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone and testosterone enanthate injections
Study: 18422205
Drug: Long-term anti-platelet
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term anti-platelet therapy
Study: 16316859
Drug: Dozozin‐2 (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dozozin‐2 (test formulation)
Study: 16316859
Drug: Cardura (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardura (reference formulation)
Study: 11128850
Drug: CHO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO treatment (glucose 60 g x L(‐1))
Study: 11128850
Drug: PLA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLA treatment (placebo drink)
Study: 11128850
Drug: RFI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: RFI treatment (restricted fluid intake with 200 mL placebo)
Study: 3698655
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg naftidrofuryl daily
Study: 26751236
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery and intraperitoneal chemotherapy (5-fluorouracil 550 mg/m²/d for 6 days, repeated monthly for 6 months)
Study: 26751236
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (oxaliplatin and 5-fluorouracil regimen every second week for 6 months)
Study: 26751236
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery and intraperitoneal chemotherapy
Study: 25323203
Drug: Narrative Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Exposure Therapy (NET-1)
Study: 22661123
Drug: Adenosine 25
Normalized name: adenosine 25 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 25 μg/kg/min
Study: 22661123
Drug: Adenosine 50
Normalized name: adenosine 50 mcg/mL-NaCl 0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 50 μg/kg/min
Study: 22661123
Drug: Adenosine 100
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine 100 μg/kg/min
Study: 22661123
Drug: Adenosine 200
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine 200 μg/kg/min
Study: 10621537
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs for inflamed pterygia
Study: 9295497
Drug: Food intake
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food intake during intestinal preparation
Study: 9295497
Drug: Fasting during
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting during intestinal preparation
Study: 31215460
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (intravenous continuous infusion of regular human insulin at a rate of 0.1 units/kg·h to 0.3 units/kg·h)
Study: 23911102
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of injectable form of tranexamic acid (500 mg in 5 mL)
Study: 23911102
Drug: Anterior nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior nasal packing with pledgets coated with tetracycline ointment
Study: 19356743
Drug: Telemedicine cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine cognitive behavioral therapy (CBT)
Study: 22706833
Drug: Face-to-face cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive behavioral therapy (CBT)
Study: 16910866
Drug: 0.4% ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% ketorolac tromethamine ophthalmic solution
Study: 16910866
Drug: 0.5% ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ketorolac tromethamine ophthalmic solution
Study: 14962400
Drug: Key-pressing actions
Normalized name: LEMON OIL, COLD PRESSED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Key-pressing actions producing auditory effects; no specific dosage or duration mentioned
Study: 9232045
Drug: Intravenous penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous penicillin G sodium, 250,000 U/kg every 24 hours
Study: 337985
Drug: Oral droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral droperidol
Study: 8355866
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam plus droperidol
Study: 29167877
Drug: Ketamine (0.23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.23 mg/kg infusion over 1 minute followed by 0.58 mg/kg/h infusion over 30 minutes and then 0.29 mg/kg/h infusion over 29 minutes)
Study: 20103540
Drug: Celiac plexus
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiac plexus block with 25 mL bupivacaine 0.25%
Study: 18928102
Drug: Paidu Baoshen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paidu Baoshen Pill (PBP) 3 g twice a day
Study: 18928102
Drug: Oxidative amylase
Normalized name: amylase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxidative amylase aldehyde enveloped capsule 5-10 capsules thrice a day
Study: 18928102
Drug: Paidu Baoshen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paidu Baoshen Pill (PBP)
Study: 16386522
Drug: Basiliximab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basiliximab (20 mg/day) on days 0 and 4 posttransplant
Study: 16386522
Drug: Daclizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (1 mg/kg per day) on days 0 and 15 posttransplant
Study: 16386522
Drug: Interleukin-2-receptor blockade
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Interleukin-2-receptor blockade
Study: 9930597
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (24% PT-IgE at 7 months)
Study: 9930597
Drug: Whole-cell pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-cell pertussis vaccine (3% PT-IgE at 7 months)
Study: 8049448
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 mg/kg IV for days 1-22, then 0.5 mg/kg for days 22-35)
Study: 3133251
Drug: Purified follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified follicle-stimulating hormone (pure-FSH)
Study: 11604193
Drug: Danazol 200
Normalized name: danazol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 200 mg vaginal suppositories three times during 2 days before administering misoprostol.
Study: 11604193
Drug: Placebo suppositories.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppositories.
Study: 31907080
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg daily lutein supplementation for 12 weeks
Study: 26755665
Drug: Pharmacist-led telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led telephone consultations (2 consultations, 4-6 weeks apart) plus a written summary and a medicines reminder chart.
Study: 24866022
Drug: Na-selenite treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na-selenite treatment (1000-μg/2 hours load, followed by 1000-μg/die)
Study: 24866022
Drug: Na-selenite treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na-selenite treatment
Study: 16055569
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine continuous wound infusion
Study: 7574757
Drug: Combined treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatments (preoperative hyperthermia, irradiation, 5-fluorouracil suppository)